First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
NCT07527923
This study is recruiting at 6 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
This study will test a study medicine called REGN20423 to see how effective it is in healthy participants (in Part A) and participants with atopic dermatitis (eczema) (in Part B). REGN20423 is a study medicine that is only used in clinical studies. REGN20423 has not previously been studied in humans.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Healthy Volunteer
- Atopic Dermatitis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Regeneron Pharmaceuticals
- Last updated on ClinicalTrials.gov
- October 7, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- Cahaba Dermatology & Skin Health Center, LLC · Birmingham, AL
Arkansas · 1
- Arkansas Research Trials · North Little Rock, AR
California · 1
- Alliance Clinical West Hills (Focus Clinical Research) · West Hills, CA
Florida · 1
- Florida International Research Center · Miami, FL
South Carolina · 1
- National Allergy and Asthma Research, LLC · North Charleston, SC
Texas · 1
- Texas Dermatology and Laser Specialists · San Antonio, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.